In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transition Therapeutics Inc.

Division of Opko Health Inc.

Latest From Transition Therapeutics Inc.

The Frost Factor: An M&A Leader's Standout Strategy For Opko Health

With CEO leadership in the biopharma industry more short-cycled than ever, billionaire entrepreneur Phillip Frost ranks as a competitor for the long game – the last man standing in an endurance test spanning four decades of exposure to every iteration of a fast-changing business model. Frost’s strategy at Opko eschews the approach of most of his CEO peers to seek therapeutic dominance in a narrow band of core competencies.

Business Strategies Deals

Opko Embarks On Transition To Profitability With Discount Buy

The life sciences company picks up Transition Therapeutics in an all-stock deal that fleshes out its pipeline.

Companies Deals

Stockwatch: biotech stock propagandists, beware!

In Allan Massie's series of historical novels set in Bordeaux from 1940, the war in Europe is followed through the lives of French civilians as the invasion turns to into the occupation, and collaboration rather than resistance becomes acceptable and even encouraged. After the liberation however, collaboration takes on a quite different connotation.

Infectious Diseases Cancer

Placebo continues winning streak in Alcobra, Transition trials

Placebos are having a good week, giving drug makers Alcobra and Transition Therapeutics troubling clinical trial results to report for their drugs meant to treat Fragile X syndrome and Alzheimer's disease.

Infectious Diseases Neurology
See All

Company Information